Last updated: 2026-10-05 21:32:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
NewcelX Ltd. (NCEL) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $2.91, with a market capitalization of $16.46M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.83 to $7.64. This page covers its latest market performance, valuation, price trends and company information.
$16.46M | |
$2.82 | |
$7.64 | |
$1.83 | |
$2.85 | |
4.05K | |
13.82K | |
-- | |
$7.64 | |
$1.83 | |
-- | |
-- |
NewcelX Ltd. (NCEL) is trading at $3.04 in after-hours trading as of 2026-10-05 20:11:00, up 6.49% ($0.19) from the regular-session close of $2.85.
After-hours trading shows how investors are pricing NCEL after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, NewcelX Ltd. (NCEL) moved from $2.89 to $2.91, representing a gain of 0.52% ($0.01).
The stock traded between $2.76 and $3.25 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 4.33 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 18.5%
NCEL is currently trading at $2.91, placing it 18.5% of the way from its 52-week low of $1.83 to its 52-week high of $7.64. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
| Employees | 4 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of NewcelX Ltd. (NCEL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.